{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078172","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.099226+00:00","generated_at":"2026-05-31T23:14:19.873294+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit","bullets":["Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.","Charge expected to negatively impact GAAP and non-GAAP EPS by ~$0.18 per diluted share.","Charge relates to up-front payments and equity premium on collaboration and licensing deals.","Results are preliminary and subject to financial close procedures; actual may vary."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078172","json":"https://secwatch.observer/filing/0001104659-24-078172.json","markdown":"https://secwatch.observer/filing/0001104659-24-078172.md","text":"https://secwatch.observer/filing/0001104659-24-078172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465924078172/0001104659-24-078172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465924078172/tm2418837d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:14:19.873294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}